Vifor Pharma's shares surged more than 15% in early trading on Monday after the Swiss drugmaker and Australia's CSL both confirmed they were talking about a potential merger.
Australian media reports have suggested a bid by biopharmaceutical giant CSL for Vifor could result in a A$10 billion deal.
"Until then, Vifor does not comment on these discussions," said the company which works on iron deficiency, nephrology and cardio-renal therapies. A successful deal would be CSL's biggest acquisition and give it access to Vifor's treatments for iron deficiency, kidney and cardio-renal diseases, as well as its production sites in Switzerland and Portugal, analysts said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Lauren Goodger and her daughter Larose have been struck down with covidYummy mummy Lauren Goodger also confirmed ex Charles Drury has moved back in as she shared three positive covid tests
Consulte Mais informação »
Earthquake, Magnitude 4.9 - EASTERN HONSHU, JAPAN - 2021 December 12, 03:31:00 UTCMagnitude: Mw 4.9, Region: EASTERN HONSHU, JAPAN, Date time: 2021-12-12 03:31:00.0 UTC, Location: 36.15 N ; 139.79 E, Depth: 71 km.
Consulte Mais informação »
Britain Increases Scrutiny of Foreign Takeovers as U.S. Deals SurgeThe U.K. is putting foreign takeovers of its businesses under greater scrutiny, complicating a popular route to overseas expansion for American companies as they spend record amounts on British acquisitions.
Consulte Mais informação »
Viaplay Partners With Comcast For Nordic Streamer’s U.S. Launch on Dec. 15 (EXCLUSIVE)Viaplay, Scandinavia’s leading streamer, is set to launch in the U.S. on Dec. 15 under a partnership with Comcast. A European challenger to global players, Viaplay will bow with more than 1,1…
Consulte Mais informação »
Parenting, Baby Names, Celebrities, and Royal News | CafeMom.com
Consulte Mais informação »
Premier League talking pointsTalking points from the Premier League weekend:
Consulte Mais informação »